Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice
Journal
Journal of thoracic disease
Journal Volume
15
Journal Issue
8
Date Issued
2023-08-31
Author(s)
Fong, Chin Heng
Meti, Nicholas
Kruser, Timothy
Weiss, Jessica
Liu, Zhihui Amy
Takami, Hirokazu
Narita, Yoshitaka
de Moraes, Fabio Ynoe
Dasgupta, Archya
Ong, Choo Khoon
Kosyak, Natalya
Pavlakis, Nicholas
Kongkham, Paul
Doherty, Mark
Leighl, Natasha B
Shultz, David B
Abstract
The role for radiotherapy or surgery in the upfront management of brain metastases (BrM) in epidermal growth factor receptor mutant (EGFRm) or anaplastic lymphoma kinase translocation positive (ALK+) non-small cell lung cancer (NSCLC) is uncertain because of a lack of prospective evidence supporting tyrosine kinase inhibitor (TKI) monotherapy. Further understanding of practice heterogeneity is necessary to guide collaborative efforts in establishing guideline recommendations.
Subjects
Brain metastases (BrM); anaplastic lymphoma kinase (ALK); epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC)
Type
journal article